Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all‐ trans retinoic acid and arsenic trioxide sensitivity
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18907 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Melissa Ng Liet Hing und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Arsenicals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Acute promyelocytic leukaemia (APL) is characterised by reciprocal translocation between the promyelocytic leukaemia (PML) gene at chromosome 15q24 and the retinoic acid receptor alpha (RARA) gene at chromosome 17q21. The resulting PML::RARA fusion gene interferes with the RARA transcriptional pathway, leading to leukaemogenesis via differentiation block and a clinical syndrome notable for life-threatening coagulopathy.1-4 APL is exquisitely sensitive to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which induce differentiation of malignant promyelocytes and proteasomal degradation of the PML::RARA fusion protein.5, 6 Patients presenting with features within the clinical, morphological and immunophenotypic spectrum of APL but lacking the pathognomonic PML::RARA fusion are known as variant APL and account for approximately 1%–2% of cases.7-11 RARA rearrangements with non-PML fusion partners predominate, with extremely rare cases involving retinoic acid receptor beta (RARB) and gamma (RARG) isoforms.8-11 Herein, we describe a patient with variant APL involving a previously unreported RARA rearrangement with the NAB2 gene at chromosome 12q13.3, which demonstrated clinical sensitivity to ATRA and ATO. A 73-year-old male presented with symptomatic anaemia. Full blood examination revealed marked pancytopenia (Table S1) and a peripheral blood film showed 30% blasts possessing distinctive bilobed nuclei (Figure 1A), while ancillary testing detected concomitant coagulopathy (Table S1). Bone marrow aspirate (BMA) revealed 76% leukaemic blasts with rare Auer rods (Figure 1B). Trephine biopsy showed an extensive blastic infiltrate with positive immunohistochemistry for CD123 and CD117, as well as CD34 positivity in 20% of blasts. Multiparameter flow cytometry revealed three blast subpopulations showing distinct separation based on CD117 and CD11b expression (Figure 1C; Supporting Information). Conventional G-banding karyotyping showed 46,XY,t(12;17)(q13;q21) (Figure 1D). PML::RARA dual fusion fluorescence in situ hybridisation (FISH) did not show PML::RARA translocation, instead showing 3 RARA signals (Figure 1E). Subsequent RARA (17q21) break-apart FISH confirmed RARA rearrangement, showing that the 3ʹ end of RARA had translocated onto chromosome 12, corresponding to the t(12;17) translocation seen by karyotyping (Figure 1F). No PML::RARA fusion transcript was detected by real-time polymerase chain reaction. RNA sequencing identified NAB2::RARA fusion transcripts, with the majority involving the 3ʹ end of NAB2 (NM_005967) exon 5 at amino acid codon 426 and a smaller proportion involving the 3ʹ end of NAB2 exon 6 at amino acid codon 490 (Figure 1G). Both were fused to the 5ʹ end of RARA (NM_00964) exon 3 at amino acid codon 60. Reciprocal RARA::NAB2 fusion transcripts involving the 3ʹ end of RARA exon 2 and the 5ʹ end of NAB2 exon 7 were also detected. A unique molecular index-based targeted DNA sequencing panel revealed mutations in TET2, ZRSR2, SRSF2 and IDH2 (Table S2). No FLT3 variant was identified. Based on morphological suspicion of APL, ATRA and prednisolone were initiated, followed by induction treatment comprising idarubicin, ATRA and ATO (Table S3) upon molecular confirmation of variant APL.12 Substantial cryoprecipitate transfusions were required to maintain a fibrinogen level above 1.5 g/L, with the cryoprecipitate requirement resolving 6 days following commencement of induction. No clinical evidence of differentiation syndrome was observed during induction. BMA 38 days post-induction revealed an excess of blasts and abnormal promyelocytes (11% of total nucleated cells) with similar immunophenotype to the diagnostic population suspicious for residual disease with an element of myeloid differentiation. RARA 17q21 break-apart FISH showed no RARA rearrangement in 200 interphase cells. The patient received an additional 2 weeks of ATRA, after which repeat BMA showed morphological complete remission with incomplete platelet count recovery (CRi) and ongoing cytogenetic remission by FISH. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) using bespoke primers targeting NAB2ex6::RARAex3 and RARAex2::NAB2ex7 transcripts showed >3 log reduction in fusion transcripts following extended induction. The patient received three cycles of ATRA/ATO consolidation, with undetectable fusion transcripts by RT-qPCR following consolidation cycle 1 (Table 1). The patient remains in CRi with no immunophenotypic or molecular evidence of measurable residual disease (MRD) 15 months postdiagnosis. The variant read frequency for the IDH2 variant was significantly reduced following induction and it was not detected after extended induction (Table S2), implying its presence in the variant APL clone and raising the possibility that mutant IDH2 may be contributing to differentiation block as a secondary cooperating mutation for leukaemogenesis in this case. A fluctuating peripheral blood monocytosis (1.3–2.1 × 109/L) was noted post-treatment (Figure S1), alongside persistent TET2, ZRSR2 and SRSF2 variants on serial bone marrow assessments (Table S2). Despite the absence of definitive morphological changes on post-treatment bone marrow biopsies, antecedent chronic myelomonocytic leukaemia is strongly suspected given the retrospective identification of a pre-existing monocytosis 6 months prior to the variant APL diagnosis. To our knowledge, this is the first reported case of variant APL with t(12;17) translocation leading to NAB2::RARA fusion. This novel APL variant presented with classic clinical and morphological features, although immunophenotypic atypia was noted. Absence of initial evidence regarding ATRA/ATO responsiveness prompted the decision to proceed with anthracycline-containing APL induction; however, achievement of persistent MRD-negative CRi following ATRA/ATO consolidation suggests that the NAB2::RARA fusion should be provisionally included in the group of ATRA/ATO-sensitive RARA rearrangements, which includes PML, NPM1, NUMA, FNDC3B, FIP1L1, TFG and IRF2BP2 partner genes.8-11 RARA fusions with PLZF, BCOR, STAT3, STAT5B and TBLR1 partner genes are reported to be ATRA/ATO-resistant and warrant management with non-APL acute myeloid leukaemia regimens.8-13 The novel partner gene NAB2 encodes NGFI-A binding protein 2 (NAB2), which represses members of the early growth response (EGR) family of transcriptional transactivators.14 NAB2 is recurrently translocated to STAT6 (signal transducer and activator of transcription 6) in solitary fibrous tumours, through which NAB2 acquires a STAT6 activation domain and is converted into a transcriptional activator of EGR1, leading to constitutive EGR activation and tumour development.15 However, the conservation of C-terminal RARA motifs is seen in NAB2::RARA fusion, consistent with other variant RARA rearrangements. We, therefore, hypothesise that the canonical repressive function of NAB2 disrupts RARA signalling, leading to impaired haematopoietic stem cell differentiation and the characteristic APL phenotype. With advances in molecular detection methods, APL with variant RARA rearrangements are increasingly being reported. Identification of the fusion partner is imperative to guide therapy and minimise the likelihood of treatment failure given the variable response to ATRA/ATO. Variant APL with NAB2::RARA rearrangement shows clinical sensitivity to ATRA and ATO with a bespoke RT-qPCR assay confirming ongoing MRD-negative remission. Melissa Ng Liet Hing, Kah Lok Chan and Ashish Bajel wrote the manuscript with helpful input from all authors. Ashish Bajel and Rithin Nedumannil provided clinical care for the patient. Melissa Ng Liet Hing, Kah Lok Chan and David A. Westerman reported morphology and flow cytometry. Georgina L. Ryland, Tamia Nguyen, Ing Soo Tiong and Piers A. Blombery performed the molecular analyses. Karen Dun and Slavisa Ninkovic performed cytogenetics and FISH analyses. All authors reviewed and approved the submitted version. The authors gratefully acknowledge funding sources, including the Wilson Centre for Blood Cancer Genomics and the Snowdome Foundation. The authors declare no conflicts of interest. This work was performed with approval by the Human Research Ethics Committee (HREC) of the Peter MacCallum Cancer Centre (Project no: 03/90, Title: Ethical oversight of pathology activity) and was conducted in accordance with the Helsinki Declaration of 1975 (revised in 2008). Written consent for publication was obtained from the patient. Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Diagnostic Haematology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
- Victorian Cancer Cytogenetics Service, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Melissa Ng Liet Hing, Georgina L Ryland, Ing Soo Tiong, Slavisa Ninkovic, Rithin Nedumannil, Piers A Blombery, Kah Lok Chan, Ashish Bajel
Zitieren
APA
Ng Liet Hing, M., Ryland, G. L., Nguyen, T., Tiong, I. S., Dun, K., Ninkovic, S., Nedumannil, R., Westerman, D. A., Blombery, P. A., Chan, K. L., & Bajel, A. (2023). Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all‐ trans retinoic acid and arsenic trioxide sensitivity. British Journal of Haematology. https://doi.org/10.1111/bjh.18907
Vancouver
Ng Liet Hing M, Ryland GL, Nguyen T, Tiong IS, Dun K, Ninkovic S, et al. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all‐ trans retinoic acid and arsenic trioxide sensitivity. British Journal of Haematology. 2023. doi:10.1111/bjh.18907
BibTeX
@article{NgLietHing2023,
author = {Ng Liet Hing, Melissa and Ryland, Georgina L and Nguyen, Tamia and Tiong, Ing Soo and Dun, Karen and Ninkovic, Slavisa and Nedumannil, Rithin and Westerman, David A and Blombery, Piers A and Chan, Kah Lok and Bajel, Ashish},
title = {Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all‐ trans retinoic acid and arsenic trioxide sensitivity},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18907}
}
EUVIMED